Oxidative Stress & Cardiovascular Disease

Product name

proANP

N-terminal fragment of atrial natriuretic propeptide 1-98

Cat-Nr.BI-20892
Range0-10 nmol/l
Sensitivity0,05 nmol/l
Incubation time3h / 30min
Sample volume10 ┬Ál
Sample type

EDTA- or Heparin plasma, serum, urine, cell culture supernatant

Sample preparation

Centrifuge freshly collected blood within one hour, test immediately or store at -20°C, for longer storage at -70°C. The stability of NT-proANP 1-98 in serum compared to plasma is lower.
4 freeze-thaw cycles are possible for plasma. 2 cycles for serum.
Urine and cell culture supernatant can be measured directly.

Reference values

Plasma median: 1,45 nmol/l

Species

Human, rat, mouse, porcine

Cross reaction

proANP (1-30): <1%, proANP (31-67): <1%, proANP (79-98): <1%,
alpha ANP (99-126): <1%, proBNP (8-29): <1%, proBNP (32-57): <1%,
proCNP (1-19): <1%, proCNP (30-50): <1%, proCNP (51-97): <1%

Tests96
MethodELISA
Intended use

Atrial natriuretic peptide is synthetisized in atrial myocytes and is stored in secretory granules as a 126 amino acid prohormone. The most important stimulus for the release of the hormone into circulation is stretch of the myocyte fibres. On release the prohormone is split into equimolar amounts of the highly biologically active proANP (99-126), also known as alpha-ANP, and the N-terminal part proANP (1-98). Alpha-ANP is rapidly cleared from the circulation with a half-life of 3-4 minutes. proANP (1-98) has a much longer half-life (60-120 min) which leads to significantly higher concentrations in blood compared to alpha-ANP. Thus, circulation levels of proANP (1-98) are less sensitive to the pulsatile secretion of ANP and may better reflect chronic levels of ANP secretion than the rapid fluctuating levels of alpha-ANP. proANP is discussed as valuable marker for e.g. sepsis or risk stratification in heart failure.

Clinical significance:
• research studies on heart failure (LVD, CHF etc)
• research studies on heart transplanted patients
• drug studies on heart transplanted patients
• risk assessment in heart failure
• risk assessment in MI patients with normal NT-proBNP levels
• monitoring of cardiac resynchronization therapy

Product informations

Back to overview